Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome - Wikidata - awgldk - TriplyDB

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

http://www.wikidata.org/entity/Q34510359

about

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxide Fitness trade-offs restrict the evolution of resistance to amphotericin B Epidemiology of invasive candidiasis: a persistent public health problem A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.Canadian clinical practice guidelines for invasive candidiasis in adults.Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.Antifungal pharmacokinetics and pharmacodynamics Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp Developments in the treatment of candidiasis: more choices and new challenges.Immunomodulatory therapy in yeast infections.Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.Determinants of mortality in non-neutropenic ICU patients with candidaemia Trends in antifungal susceptibility testing using CLSI reference and commercial methods.Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.Amphotericin B use in children: conventional and lipid-based formulations.The evolving role of antifungal susceptibility testing.Current status of antifungal resistance and its impact on clinical practice.Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa.Emergence of Magnusiomyces capitatus infections in Western Nepal.Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B.Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin.Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens.In vitro activity of echinocandins against 562 clinical yeast isolates from a Romanian multicentre study.Antifungal drugs: predicting clinical efficacy with pharmacodynamics.Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.[Reevaluation of Candida susceptibility to amphotericin B: comparative study using isolates from three hospitals in the state of Rio Grande do Sul].Enhanced Killing and Antibiofilm Activity of Encapsulated Cinnamaldehyde against Candida albicans.A new small-molecule KRE2 inhibitor against invasive Candida parapsilosis infection.Efficacy of nasal irrigation with 200 μg/mL amphotericin B after functional endoscopic sinus surgery: a randomized, placebo-controlled, double-blind study.Diagnosis and management of a fatal case of sepsis caused by Candida parapsilosis sensu stricto in a neonate with omphalocele.Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.Fungal persister cells: The basis for recalcitrant infections?Treatment of Invasive Candidiasis: A Narrative Review

P2860

Q27025299-DD14D1C4-AD9C-47A5-8181-0B5D49BA9799 Q28481546-4EC04B2E-7B8D-4CA9-8FEB-57BA0E4D8B83 Q28534687-AB3E9165-7C32-4EAD-9CCB-79F4880FAC2D Q29616758-76B0B829-C326-4269-AACD-5C72A8880BC3 Q34108567-1A121135-C6AF-4649-B429-A9E64D53D12F Q34237335-6944B0F7-E724-4E1A-A49D-AB228C77F6C3 Q34290134-928415B7-6F6A-44FD-AA1A-3521807DB9B4 Q35663841-D701FDE6-B8BB-4F0E-8B07-BAE1D5FDD7C1 Q36022880-6BFE74A2-E971-491B-8FED-F4FE6F4AA8A4 Q36022956-38FA853A-092D-4A66-8F7E-3E87A101B1AD Q36172242-1F6643D9-7FFF-4BA3-9BF1-421329CF42C0 Q36314322-63696110-A81F-4217-92B9-10A1DA152942 Q36623050-82DFEDE1-6FEC-4FF9-BDA1-16317EC81BAB Q36723814-0D24D100-A9B4-42D9-B262-AED81E211352 Q37029222-269486D3-4B8C-4445-9345-9796D29449D9 Q37360312-1343F365-C6A9-4B64-82BC-AF3C27EE0924 Q37557695-684D09DF-EBFB-4C73-8652-9A605769BADE Q37664411-CFAC10A4-D4DB-4E24-B332-DC9813862634 Q37854727-21567EA0-AEDD-475B-BD0F-53FA69A1C9C4 Q38095809-6C9C8123-01CE-4D86-A4FA-391ECC777390 Q38205859-830D66DE-A764-4593-8C37-1503BFDF9803 Q38236893-6410C788-750E-4425-B159-7B96D0C46B22 Q39030370-090769FC-1A8D-43D7-9F27-1E514FD1899A Q40413237-8E9CC873-FEA5-46F4-AACD-F37A0C3B15C8 Q41017112-D0C10D9E-D508-4B8F-BB02-0F1D260AA5B0 Q41066158-42210C0B-032F-4E1B-98FA-503DDE4CA550 Q41071187-F439CA79-5E8E-4B18-979F-C99A22F228FD Q41600855-0FB05188-7642-4C3B-B2DC-49FA4EC2F2DF Q41989571-46FAE8A3-8AFE-4121-B03C-1F260054B37B Q42723597-9879DC19-A454-4737-90ED-93AF6242818A Q42929602-759EB989-95EB-4310-AE24-0E1FBC464145 Q46681089-7C319C3C-C2B3-468D-870E-08C0AE905C1B Q47149925-D8F0CA33-6993-4A87-A45A-450FD07A191C Q47702018-1847440D-0B3C-48FD-812A-9FB9A21BAFFB Q47725041-78C68BCE-5166-49FD-B5FD-36AC4A5BB14A Q48514102-353758BD-5B51-4FB8-A3CE-404E39203D6D Q49708514-ECA52CB9-5F5B-462A-B4B2-C906D0E27F33 Q58602400-9E81C808-F50F-4DA5-9924-44C111AF7D87 Q58772447-6BBD01D4-4DB2-4227-AD4B-BD4C37F57100

P2860

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

http://www.wikidata.org/entity/Q34510359

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@ast

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@en

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@nl

type

label

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@ast

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@en

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@nl

prefLabel

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@ast

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@en

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@nl

P1433

Q34510359-05A0BE0D-B3B5-4A99-ADE4-87D92EF39982

P1476

Q34510359-3B65D852-1C57-4880-8254-0B317EB33A85

P2093

Q34510359-232B131A-D616-41D2-94E4-388AC7316714

Q34510359-2C573DF2-04F9-4AC1-82BC-D94DA851B447

Q34510359-7F4A7FE9-3287-4A48-9AE1-C0DB4E2AF2F5

Q34510359-8074EC46-9171-4E37-B529-DAF9E6115CB2

Q34510359-8661F8AE-029E-4A81-B22A-67626B6798F9

Q34510359-86D81E32-0F40-4060-891E-D4B581D027F5

Q34510359-883C119C-744C-4A7B-AC63-E95F488AD3E5

Q34510359-99EC4EDF-2773-4387-81D1-3A9EEFF0E6EA

Q34510359-B2AB882D-C4D9-4994-A4DC-1777334D1448

Q34510359-C1F6799A-C0C3-4C45-BAEE-DD8DCDB57732

P2860

Q34510359-0B4F8631-CF6C-4E4E-B6BC-F8F8D3ED5186

Q34510359-17A60CCB-C2A6-43EC-8D76-2F7420ACA893

Q34510359-20512D21-C732-461E-8A72-FFBB3EA0E6C6

Q34510359-7023D518-845E-4D22-B887-B0C7CF1D3F60

Q34510359-76FA3EF5-596F-4F74-8FB7-1F8A01BD2657

Q34510359-7762E032-6E7B-41B9-B1F7-0A668DBD48E6

Q34510359-78FECFC8-9B0F-494E-8E84-56B6287C2CE1

Q34510359-8FB66242-43FC-43E8-B685-15DC0EE63632

Q34510359-ACD81BC3-9B1B-40A4-A163-3FFB711DC7D2

Q34510359-AF32EA45-54D0-4EE9-8AC3-CFDC74E101C0

P304

Q34510359-3871272D-8539-43E1-8E02-03D4FC3164F1

P31

Q34510359-F870532B-B6CD-490C-B70D-C7483F6E1D20

P356

Q34510359-88A28C14-0EE7-43F0-8B7F-2C227147DF12

P407

Q34510359-F8C9603F-DC25-4E63-939E-922AADF49953

P433

Q34510359-94EE6722-A18E-4305-884E-C07327B97808

P478

Q34510359-6413B10E-C2AA-4F4E-943C-5D1E16F3CC51

P577

Q34510359-4B649EFD-C8C9-48EB-8377-409D39D669F9

P5875

Q34510359-86D1DA58-1E53-4F9C-9D0C-2A137BAB262E

P698

Q34510359-88957EC0-C29B-4F84-B2D2-8495461F5366

P932

Q34510359-5AFFF801-3B24-4452-B6B0-427D27ED4E06

P356

AAC.50.4.1287-1292.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Evaluation of amphotericin B i ...... ation with therapeutic outcome

@en

P2093

Andre N Sofair

http://www.w3.org/2001/XMLSchema#string

Benjamin J Park

http://www.w3.org/2001/XMLSchema#string

Beth A Arthington-Skaggs

http://www.w3.org/2001/XMLSchema#string

Brian D Plikaytis

http://www.w3.org/2001/XMLSchema#string

David W Warnock

http://www.w3.org/2001/XMLSchema#string

Lee H Harrison

http://www.w3.org/2001/XMLSchema#string

Mario D Hairston

http://www.w3.org/2001/XMLSchema#string

Maureen Phelan

http://www.w3.org/2001/XMLSchema#string

Meral A Ciblak

http://www.w3.org/2001/XMLSchema#string

Naureen Iqbal

http://www.w3.org/2001/XMLSchema#string

P2860

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest

Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.

Has antifungal susceptibility testing come of age?

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.

Candida dubliniensis fungemia: the first four cases in North America.

P304

1287-1292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.4.1287-1292.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7209157

http://www.w3.org/2001/XMLSchema#string

P698

16569842

http://www.w3.org/2001/XMLSchema#string

P932

1426914

http://www.w3.org/2001/XMLSchema#string